| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/30/2001 | WO2001062784A2 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | WO2001062783A1 A novel polypeptide-human split complex 69 and the polynucleotide encoding said polypeptide |
| 08/30/2001 | WO2001062778A2 Tumour-specific animal proteins |
| 08/30/2001 | WO2001062777A1 Bombesin analogs for treatment of cancer |
| 08/30/2001 | WO2001062776A1 Hla binding peptides and their uses |
| 08/30/2001 | WO2001062775A2 Novel antiarrhythmic peptides |
| 08/30/2001 | WO2001062769A1 Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates |
| 08/30/2001 | WO2001062760A2 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR |
| 08/30/2001 | WO2001062757A1 Novel compounds |
| 08/30/2001 | WO2001062750A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 08/30/2001 | WO2001062742A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| 08/30/2001 | WO2001062736A1 Aryl fused azapolycyclic compounds |
| 08/30/2001 | WO2001062733A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | WO2001062731A1 Pyridine-amidines as modulators of p38 map kinase |
| 08/30/2001 | WO2001062729A1 Novel compounds |
| 08/30/2001 | WO2001062728A1 Novel compounds |
| 08/30/2001 | WO2001062725A2 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | WO2001062721A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062714A1 Novel phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062668A2 Sulfur containing compounds |
| 08/30/2001 | WO2001062341A2 Combination product for the treatment of obesity |
| 08/30/2001 | WO2001062300A2 Caspase activated prodrugs therapy |
| 08/30/2001 | WO2001062298A2 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 08/30/2001 | WO2001062297A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | WO2001062289A2 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 08/30/2001 | WO2001062288A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | WO2001062286A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | WO2001062281A1 Pai-2 conjugates for the treatment and imaging of cancer |
| 08/30/2001 | WO2001062275A1 Adjuvant treatment by in vivo activation of dendritic cells |
| 08/30/2001 | WO2001062274A1 Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors |
| 08/30/2001 | WO2001062261A1 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 08/30/2001 | WO2001062252A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062251A1 Tyrosine kinase inhibitors |
| 08/30/2001 | WO2001062239A2 Novel compositions and uses of dictyostatin compounds |
| 08/30/2001 | WO2001062235A2 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| 08/30/2001 | WO2001062234A2 Dosing regimen |
| 08/30/2001 | WO2001062156A1 Novel indocyanine dyes |
| 08/30/2001 | WO2001016335A3 Stromelysin-homologous novel mmp-27 matrix metalloproteinase |
| 08/30/2001 | WO2001012806A3 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 08/30/2001 | WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 08/30/2001 | WO2001012199A3 Methoxyamine potentiation of temozolomide anti-cancer activity |
| 08/30/2001 | WO2001010457A3 Pharmaceutical compositions containing tripeptides |
| 08/30/2001 | WO2001009325A3 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 08/30/2001 | WO2001009187A3 Human monoclonal antibodies to her2/neu |
| 08/30/2001 | WO2001002568A3 Human genes and gene expression products |
| 08/30/2001 | WO2001002540A3 Adenoviral vectors for treating disease |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | US20010018531 Therapy for mammary or colon tumors |
| 08/30/2001 | US20010018511 Anticancer agent |
| 08/30/2001 | US20010018456 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis |
| 08/30/2001 | US20010018451 Raloxifene, tamoxifen |
| 08/30/2001 | US20010018445 Thalidomide |
| 08/30/2001 | US20010018440 L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections |
| 08/30/2001 | US20010018430 Anticancer agents, psoriasis, restenosis, atherosclerosis |
| 08/30/2001 | US20010018425 New compounds for the treatment of cancer |
| 08/30/2001 | US20010018422 Anticancer agents |
| 08/30/2001 | US20010018212 Molecular weight of 14,000 to 24,000 daltons; treating infectious diseases and malignant tumors with said protein |
| 08/30/2001 | US20010018204 Administering composition of tissure factor pathway inhibitor, homolog or active fragment with anti-proliferative activity; treating angiogenesis related diseases; cancer; arthritis; macular degeneration; diabetic retinopathy |
| 08/30/2001 | US20010018198 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same |
| 08/30/2001 | US20010018076 Anti-cancer agents isolated from buckwheat rhizomes (Fagospyrum cymosum); high powered liquid chromatography; purity; tannins |
| 08/30/2001 | US20010018054 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 08/30/2001 | US20010018053 Methods for treating disease states comprising administration of low levels of antibodies |
| 08/30/2001 | US20010018041 Lymphomas, leukemia |
| 08/30/2001 | CA2406864A1 Simultaneous stimulation and concentration of cells |
| 08/30/2001 | CA2402114A1 Sulfur containing compounds |
| 08/30/2001 | CA2401367A1 Activated vitronectin as a marker of angiogenesis detected with phage antibodies |
| 08/30/2001 | CA2401195A1 Pai-2 conjugates for the treatment and imaging of cancer |
| 08/30/2001 | CA2401190A1 Pyridine-amidines as modulators of p38 map kinase |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | CA2401070A1 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | CA2401063A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 08/30/2001 | CA2401031A1 Tlp peptides and dna sequences coding the same |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400948A1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| 08/30/2001 | CA2400923A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400896A1 Novel compositions and uses of dictyostatin compounds |
| 08/30/2001 | CA2400875A1 Tyrosine kinase inhibitors |
| 08/30/2001 | CA2400874A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | CA2400842A1 Novel compounds |
| 08/30/2001 | CA2400831A1 Estrogen receptor beta variants and methods of detection thereof |
| 08/30/2001 | CA2400823A1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 08/30/2001 | CA2400797A1 Therapeutic agents |
| 08/30/2001 | CA2400661A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | CA2400636A1 Hybrid cell vaccines |
| 08/30/2001 | CA2400622A1 Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400215A1 Hla binding peptides and their uses |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2400040A1 Integrin antagonists |
| 08/30/2001 | CA2399999A1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | CA2399418A1 Metalloproteinase inhibitors for the treatment of respiratory diseases |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | CA2397813A1 Method and reagent for the inhibition of grid |
| 08/30/2001 | CA2397705A1 Compounds related to or derived from gfr.alpha.4 and their use |
| 08/30/2001 | CA2397558A1 Dosing regimen |